A large number of therapeutic drugs currently on the market involve G-protein coupled receptors (GPCR) in their mechanisms of action. However there is still great potential for further development in this area.
Under the terms of the collaboration, ChemDiv will apply its integrated synthetic and medicinal chemistry capabilities and collaborate with Berlex’s scientists in the search for new disease therapies. Financial terms were not disclosed.
“We are looking forward to the opportunity to work with Berlex and view this as further validation of our discovery chemistry expertise. ChemDiv’s integrated drug discovery capabilities provide an excellent fit for Berlex and we hope that our collaborative relationship will be a long-standing one,” said Alexander Kiselyov, executive VP of R&D at ChemDiv.